

DAFTAR PUSTAKA

- Ambrosy, A.P., Fonarow, G.C., Butler, J., Chioncel, O., Greene, S.J., Vaduganathan, M., dkk., 2014. The Global Health and Economic Burden of Hospitalizations for Heart Failure. *Journal of the American College of Cardiology*, **63**: 1123–1133.
- Benjamin, E.J., Muntner, P., Alonso, A., Bittencourt, M.S., Callaway, C.W., Carson, A.P., dkk., 2019. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. *Circulation*, **139**: .
- Böhm, M., Young, R., Jhund, P.S., Solomon, S.D., Gong, J., Lefkowitz, M.P., dkk., 2017. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. *European Heart Journal*, **38**: 1132–1143.
- BPOM, 2012. *Pedoman Monitoring Efek Samping Obat (MESO) Bagi Tenaga Kesehatan*. Direktorat Pengawasan Distribusi Produk Terapeutik dan PKRT Badan POM RI, Jakarta.
- Braunwald, E., 2015. The war against heart failure: the Lancet lecture. *The Lancet*, **385**: 812–824.
- Brunton, L.L., Dandan, R.H., dan Knolmann, B.C., 2018. *Goodman & Gilman's : The Pharmacological Basis of Therapeutics*, 13th ed. Mc Graw Hill, New York.
- Butler, J., Braunwald, E., dan Gheorghiade, M., 2014. Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials. *JAMA*, **312**: 789.
- Chang, P., Wang, C., Hsiao, F., Wen, M., Huang, C., Chou, C., dkk., 2020. Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan. *ESC Heart Failure*, **7**: 3003–3012.
- Chin, K.L., Zomer, E., Wang, B.H., dan Liew, D., 2019. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. *Heart, Lung and Circulation*, S1443950619302987.
- Cohn, J.N., 2001. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. *The New England Journal of Medicine*, **9**.
- Dharmarajan, K., Hsieh, A.F., Lin, Z., Bueno, H., Ross, J.S., Horwitz, L.I., dkk., 2013. Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. *JAMA*, **309**: 355.
- Farmakis, D., Parissis, J., dan Filippatos, G., 2015. *Acute Heart Failure: Epidemiology, Classification, and Pathophysiology*. Oxford University Press.
- Gomez-Soto, F.M., Andrey, J.L., Garcia-Egido, A.A., Escobar, M.A., Romero, S.P., Garcia-Arjona, R., dkk., 2011. Incidence and mortality of heart

- failure: A community-based study. *International Journal of Cardiology*, **151**: 40–45.
- Granger, C.B., McMurray, J.J.V., Yusuf, S., Held, P., Michelson, E.L., Olofsson, B., dkk., 2003. Effects of candesartan in patients with chronic heart failure. *THE LANCET*, **362**: 5.
- Heidenreich, P.A., Albert, N.M., Allen, L.A., Blumke, D.A., Butler, J., Fonarow, G.C., dkk., 2013. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association. *Circulation: Heart Failure*, **6**: 606–619.
- Heran, B.S., Musini, V.M., Bassett, K., Taylor, R.S., dan Wright, J.M., 2012. Angiotensin receptor blockers for heart failure. *Cochrane Database of Systematic Reviews*, .
- Jones, N.R., Hobbs, F.R., dan Taylor, C.J., 2017. Prognosis following a diagnosis of heart failure and the role of primary care: a review of the literature. *BJGP Open*, **1**: BJGP-2016-0021.
- Katzung, B.G., 2018. *Basic & Clinical Pharmacology*, 14th ed. LANGE Medical Book : Mc Graw Hill, New York.
- Krim, S.R., Vivo, R.P., Krim, N.R., Qian, F., Cox, M., Ventura, H., dkk., 2013. Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. *JACC: Heart Failure*, **1**: 345–352.
- MacDonald, M.R., Tay, W.T., Teng, T.K., Anand, I., Ling, L.H., Yap, J., dkk., 2020. Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. *Journal of the American Heart Association*, **9**: .
- Maggioni, A.P., Dahlström, U., Filippatos, G., Chioncel, O., Leiro, M.C., Drozd, J., dkk., 2013. EUR Observational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). *European Journal of Heart Failure*, **15**: 808–817.
- McMurray, J.J.V., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., dkk., 2014. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. *New England Journal of Medicine*, **371**: 993–1004.
- Mogensen, U.M., Gong, J., Jhund, P.S., Shen, L., Køber, L., Desai, A.S., dkk., 2018. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF): Effect of sacubitril/valsartan on recurrent events. *European Journal of Heart Failure*, **20**: 760–768.
- Moliner-Abós, C., Rivas-Lasarte, M., Pamies Besora, J., Fluvià-Brugues, P., Solé-González, E., Mirabet, S., dkk., 2019. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review. *Cardiovascular Drugs and Therapy*, **33**: 307–314.
- Park, S.-K., Hong, S.-H., Kim, H., Kim, S., dan Lee, E.-K., 2019. Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea. *Clinical Therapeutics*, **41**: 1066–1079.

- Parker, R.B., Nappi, J.M., dan Cavallari, L.H., 2017. Chronic Heart Failure, dalam: *Pharmacotherapy : A Pathophysiologic Approach*. Mc Graw Hill, New York.
- Peat, J., Mellis, C., Williams, K., dan Xuan, W., 2001. *Health Science Research : A Handbook of Quantitative Methods*. Allen & Unwin, Australia.
- PERKI, 2015. *Pedoman Tata Laksana Gagal Jantung*. Perhimpunan Dokter Spesialis Kardiovaskular, Jakarta.
- Pitt, B., 2004. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHEsus studies. *Molecular and Cellular Endocrinology*, **217**: 53–58.
- Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., dkk., 2016a. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, **37**: 2129–2200.
- Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G.F., Coats, A.J.S., dkk., 2016b. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, **37**: 2129–2200.
- Reyes, E.B., Ha, J.-W., Firdaus, I., Ghazi, A.M., Phrommintikul, A., Sim, D., dkk., 2016. Heart failure across Asia: Same healthcare burden but differences in organization of care. *International Journal of Cardiology*, **223**: 163–167.
- Ruppar, T.M., Cooper, P.S., Mehr, D.R., Delgado, J.M., dan Dunbar-Jacob, J.M., 2016. Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials. *Journal of the American Heart Association*, **5** : .
- Savarese, G., Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, Lund, L.H., Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, dan Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden, 2017. Global Public Health Burden of Heart Failure. *Cardiac Failure Review*, **03**: 7.
- Sikka, R., Xia, F., dan Aubert, R.E., 2005. Estimating Medication Persistency Using Administrative Claims Data. *THE AMERICAN JOURNAL OF MANAGED CARE*, **11**: 9.
- Solomon, S.D., Claggett, B., Desai, A.S., Packer, M., Zile, M., Swedberg, K., dkk., 2016. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine

- Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. *Circulation: Heart Failure*, **9**: .
- Stewart, S., Jenkins, A., Buchan, S., McGuire, A., Capewell, S., dan McMurray, J.J.J.V., 2002. The current cost of heart failure to the National Health Service in the UK. *European Journal of Heart Failure*, **4**: 361–371.
- Tai, C., Gan, T., Zou, L., Sun, Y., Zhang, Y., Chen, W., dkk., 2017. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. *BMC Cardiovascular Disorders*, **17**: 257.
- Tan, N.Y., Sangaralingham, L.R., Sangaralingham, S.J., Yao, X., Shah, N.D., dan Dunlay, S.M., 2020. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction. *JACC: Heart Failure*, **8**: 43–54.
- Uppsala Monitoring Centre dan WHO Collaborating Centre for International Drug Monitoring, 2000. *Safety Monitoring of Medicinal Products: Guidelines for Setting up and Running a Pharmacovigilance Centre*. Uppsala Monitoring Centre, Uppsala.
- Vardeny, O., Miller, R., dan Solomon, S.D., 2014. Combined Nephilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure. *JACC: Heart Failure*, **2**: 663–670.
- Wells, B.G., Schwinghammer, T.L., DiPiro, J.T., dan DiPiro, C.V., 2017. *Pharmacotherapy Handbook*, 10th ed. Mc Graw Hill, New York.
- Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E., Colvin, M.M., dkk., 2016. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*, **134**: .
- Yancy, C.W., Jessup, M., Butler, J., Casey, D.E., Drazner, M.H., Fonarow, G.C., dkk., 2013. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*, **128**: 88.